Stroke Research

Stroke is classified as both a neurological and a cardiovascular disease, as it is a disruption in blood supply to the brain which causes the neurological abnormalities. There are two types of stroke; ischemic and hemorrhagic.

Stroke Research Products Targets

Products for Stroke Research - Page 65

Cat.No. Product Name Information/Activity
BCC7898 A 887826 A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo.
BCC5067 Ambroxol HCl Na<sup>+</sup> channel blocker,AmbroxolHCl is a potent inhibitor of the neuronal Na+ channels, inhibits TTX-resistant Na+ currents with IC50 of 35.2 μM and 22.5 μM for tonic and phasic block, inhibits TTX-sensitive Na+ currents with IC50 of 100 μM. Phase 3.
BCC4378 Carbamazepine Carbamazepine, a sodium channel blocker, is an anticonvulsant drug.
BCC7439 Co 102862 181144-66-1
BCC1578 Flecainide acetate Flecainide acetate (R-818) is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
BCC6270 Huwentoxin IV 526224-73-7
BCC6358 ICA 121431 ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 µM).
BCC6327 Jingzhaotoxin III 925463-91-8
BCC7618 KC 12291 hydrochloride 181936-98-1
BCC7794 Licarbazepine 29331-92-8